Patricia R Peter1, Beatrice C Lupsa2. 1. Section of Endocrinology, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, FMP 106, P.O. Box 208020, New Haven, CT, 06520, USA. patricia.peter@yale.edu. 2. Section of Endocrinology, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, FMP 106, P.O. Box 208020, New Haven, CT, 06520, USA.
Abstract
PURPOSE OF REVIEW: Our goal is to discuss how to personalize the management of patients with type 2 diabetes by adjusting glycemic targets and tailoring medical therapy to account for unique patient characteristics. RECENT FINDINGS: We review the pharmacotherapeutic options for the management of type 2 diabetes, focusing on potential advantages and disadvantages of each class of agents. We also discuss how to approach specific patient subpopulations and propose a conceptual framework for incorporating these factors into clinical practice. As the diabetes treatment landscape rapidly expands, physicians have the exciting opportunity to offer patients increasingly individualized care.
PURPOSE OF REVIEW: Our goal is to discuss how to personalize the management of patients with type 2 diabetes by adjusting glycemic targets and tailoring medical therapy to account for unique patient characteristics. RECENT FINDINGS: We review the pharmacotherapeutic options for the management of type 2 diabetes, focusing on potential advantages and disadvantages of each class of agents. We also discuss how to approach specific patient subpopulations and propose a conceptual framework for incorporating these factors into clinical practice. As the diabetes treatment landscape rapidly expands, physicians have the exciting opportunity to offer patients increasingly individualized care.
Entities:
Keywords:
GLP-1 agonists; Metformin; SGLT-2 inhibitors; Type 2 diabetes
Authors: Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: Steve Bain; Eric Druyts; Chakrapani Balijepalli; Carl A Baxter; Craig J Currie; Romita Das; Richard Donnelly; Kamlesh Khunti; Haya Langerman; Paul Leigh; Gaye Siliman; Kristian Thorlund; Kabirraaj Toor; Jiten Vora; Edward J Mills Journal: Diabetes Obes Metab Date: 2016-12-23 Impact factor: 6.577
Authors: Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman Journal: N Engl J Med Date: 2016-06-14 Impact factor: 91.245
Authors: Ling Li; Jiantong Shen; Malgorzata M Bala; Jason W Busse; Shanil Ebrahim; Per Olav Vandvik; Lorena P Rios; German Malaga; Evelyn Wong; Zahra Sohani; Gordon H Guyatt; Xin Sun Journal: BMJ Date: 2014-04-15